Global Biodefense Market By Product (Anthrax, Botulism, Smallpox, Nuclear/Radiation, and Other Products), By Application (Civilian, and Military), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: July 2024
Report ID: 21643
Number of Pages: 302
Format:

- - 1. Biodefense Market Introduction
    1.1. Definition
    1.2. Taxonomy
    1.3. Research Scope
  - 2. Executive Summary
    2.1. Key Findings by Major Segments
    2.2. Top strategies by Major Players
  - 3. Global Biodefense Market Overview
    3.1. Biodefense Market Dynamics
    3.1.1. Drivers
    3.1.2. Opportunities
    3.1.3. Restraints
    3.1.4. Challenges
    3.2. PESTLE Analysis
    3.3. Opportunity Map Analysis
    3.4. PORTER'S Five Forces Analysis
    3.5. Market Competition Scenario Analysis
    3.6. Product Life Cycle Analysis
    3.7. Opportunity Orbits
    3.8. Manufacturer Intensity Map
  - 4. Global Biodefense Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    4.1. Global Biodefense Market Analysis by Type: Introduction
    4.2. Market Size and Forecast by Region
    4.3. Anthrax
    4.4. Smallpox
    4.5. Botulism
    4.6. Radiation/Nuclear
  - 5. Global Biodefense Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    5.1. Global Biodefense Market Analysis by Application: Introduction
    5.2. Market Size and Forecast by Region
    5.3. US Military Market
    5.4. US Civilian Market
    5.5. Non-US Market
  - 6. Global Biodefense Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    6.1. North America
    6.1.1. North America Biodefense Market: Regional Trend Analysis
    6.1.1.1. US
    6.1.1.2. Canada
    6.1.1.3. Mexico
    6.2. Europe
    6.2.1. Europe Biodefense Market: Regional Trend Analysis
    6.2.1.1. Germany
    6.2.1.2. France
    6.2.1.3. UK
    6.2.1.4. Russia
    6.2.1.5. Italy
    6.2.1.6. Rest of Europe
    6.3. Asia-Pacific
    6.3.1. Asia-Pacific Biodefense Market: Regional Trend Analysis
    6.3.1.1. China
    6.3.1.2. Japan
    6.3.1.3. Korea
    6.3.1.4. India
    6.3.1.5. Rest of Asia
    6.4. Latin America
    6.4.1. Latin America Biodefense Market: Regional Trend Analysis
    6.4.1.1. Brazil
    6.4.1.2. Argentina
    6.4.1.3. Rest of Latin America
    6.5. Middle East and Africa
    6.5.1. Middle East and Africa Biodefense Market: Regional Trend Analysis
    6.5.1.1. GCC
    6.5.1.2. South Africa
    6.5.1.3. Israel
    6.5.1.4. Rest of MEA
- - 7. Global Biodefense Market Competitive Landscape, Market Share Analysis, and Company Profiles
    7.1. Market Share Analysis
    7.2. Company Profiles
    7.3. Emergent Biosolutions
    7.3.1. Company Overview
    7.3.2. Financial Highlights
    7.3.3. Product Portfolio
    7.3.4. SWOT Analysis
    7.3.5. Key Strategies and Developments
    7.4. Hytest
    7.4.1. Company Overview
    7.4.2. Financial Highlights
    7.4.3. Product Portfolio
    7.4.4. SWOT Analysis
    7.4.5. Key Strategies and Developments
    7.5. GSK
    7.5.1. Company Overview
    7.5.2. Financial Highlights
    7.5.3. Product Portfolio
    7.5.4. SWOT Analysis
    7.5.5. Key Strategies and Developments
    7.6. Sanofi
    7.6.1. Company Overview
    7.6.2. Financial Highlights
    7.6.3. Product Portfolio
    7.6.4. SWOT Analysis
    7.6.5. Key Strategies and Developments
    7.7. PharmAthene
    7.7.1. Company Overview
    7.7.2. Financial Highlights
    7.7.3. Product Portfolio
    7.7.4. SWOT Analysis
    7.7.5. Key Strategies and Developments
    7.8. Bavarian Nordic
    7.8.1. Company Overview
    7.8.2. Financial Highlights
    7.8.3. Product Portfolio
    7.8.4. SWOT Analysis
    7.8.5. Key Strategies and Developments
    7.9. SIGA Technologies
    7.9.1. Company Overview
    7.9.2. Financial Highlights
    7.9.3. Product Portfolio
    7.9.4. SWOT Analysis
    7.9.5. Key Strategies and Developments
    7.10. Arbutus Biopharma
    7.10.1. Company Overview
    7.10.2. Financial Highlights
    7.10.3. Product Portfolio
    7.10.4. SWOT Analysis
    7.10.5. Key Strategies and Developments
    7.11. DynPort Vaccine
    7.11.1. Company Overview
    7.11.2. Financial Highlights
    7.11.3. Product Portfolio
    7.11.4. SWOT Analysis
    7.11.5. Key Strategies and Developments
    7.12. Xoma Corporation
    7.12.1. Company Overview
    7.12.2. Financial Highlights
    7.12.3. Product Portfolio
    7.12.4. SWOT Analysis
    7.12.5. Key Strategies and Developments
    7.13. Ichor Medical Systems
    7.13.1. Company Overview
    7.13.2. Financial Highlights
    7.13.3. Product Portfolio
    7.13.4. SWOT Analysis
    7.13.5. Key Strategies and Developments
    7.14. Aeolus Pharmaceuticals
    7.14.1. Company Overview
    7.14.2. Financial Highlights
    7.14.3. Product Portfolio
    7.14.4. SWOT Analysis
    7.14.5. Key Strategies and Developments
    7.15. Achaogen
    7.15.1. Company Overview
    7.15.2. Financial Highlights
    7.15.3. Product Portfolio
    7.15.4. SWOT Analysis
    7.15.5. Key Strategies and Developments
    7.16. Elusys Therapeutics
    7.16.1. Company Overview
    7.16.2. Financial Highlights
    7.16.3. Product Portfolio
    7.16.4. SWOT Analysis
    7.16.5. Key Strategies and Developments
    7.17. Dynavax Technologies
    7.17.1. Company Overview
    7.17.2. Financial Highlights
    7.17.3. Product Portfolio
    7.17.4. SWOT Analysis
    7.17.5. Key Strategies and Developments
    7.18. Cleveland BioLabs
    7.18.1. Company Overview
    7.18.2. Financial Highlights
    7.18.3. Product Portfolio
    7.18.4. SWOT Analysis
    7.18.5. Key Strategies and Developments
    7.19. Soligenix
    7.19.1. Company Overview
    7.19.2. Financial Highlights
    7.19.3. Product Portfolio
    7.19.4. SWOT Analysis
    7.19.5. Key Strategies and Developments
    7.20. Alnylam Pharmaceuticals
    7.20.1. Company Overview
    7.20.2. Financial Highlights
    7.20.3. Product Portfolio
    7.20.4. SWOT Analysis
    7.20.5. Key Strategies and Developments
    8. Assumptions and Acronyms
    9. Research Methodology
    10. Contact
- XOMA corporation
- Altimmune Inc.
- Emergent Biosolutions Inc.
- Dynavax Technologies Corporation.
- SIGA Technologies.
- Elusys Therapeutics Inc.
- Ichor Medical Systems.
- Dynport Vaccine Company.
- Cleveland Biolabs.
- Bavarian Nordic.
- Ology Bioservices.
- Alnylam Pharmaceuticals Inc.
- Other Key Players
Settings

Related Reports

Our Clients

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $6,000 $3,999 USD / per unit save 24%	Multi User $8,000 $5,999 USD / per unit save 28%	Corporate User $10,000 $6,999 USD / per unit save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 3,999)	Buy Now ($ 5,999)	Buy Now ($ 6,999)